Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer

75Citations
Citations of this article
84Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The role of radiation in locally advanced unresectable pancreatic cancer (LAPC) is controversial. Randomized trials evaluating standard doses of chemoradiation have not shown a significant benefit from the use of consolidative radiation. Results from non-randomized studies of 3-5-fraction stereotactic body radiotherapy (SBRT) have been similar to standard chemoradiation, but with less toxicity and a shorter treatment time. Doses of SBRT have been reduced to subablative levels for the sake of tolerability. The benefit of both options is unclear. In contrast, ablative doses can be delivered using an SBRT technique in 15-28 fractions. The keys to the delivery of ablative doses are computed tomography (CT) image guidance and respiratory gating. Higher doses have resulted in encouraging long-term survival results. In this review, we present a comprehensive solution to achieving ablative doses for selected patients with pancreatic tumors by using a combination of classical, modern and novel concepts of radiotherapy: fractionation, CT image guidance, respiratory gating, intentional dose heterogeneity, and simultaneous integrated protection.

Cite

CITATION STYLE

APA

Crane, C. H. (2016). Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer. In Journal of Radiation Research (Vol. 57, pp. i53–i57). Oxford University Press. https://doi.org/10.1093/jrr/rrw016

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free